New Drug: RTL 1000
Submitted by art on Fri, 2007-02-02 08:22.
Announcement of another drug being worked on:
QSV Biologics and Artielle ImmunoTherapeutics announced the signing of
a contract for the process development and cGMP manufacturing of RTL
1000 for multiple sclerosis. RTL 1000, licensed by Artielle from
Oregon Health & Science University, is a Recombinant T cell receptor
Ligand (RTL) that can treat a wide range of autoimmune diseases.